Stock Ratings / Health Care / LNSR / financials

QTEX (31) MBOT (41) DAVI (47) SKIN (36) ⌘ Pro Terminal →

LENSAR Inc. (LNSR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$5.84 -2.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.81

LENSAR Inc. (LNSR) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $73.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LNSR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, LENSAR Inc. (NASDAQ: LNSR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $5.84 (-2.18% 1D, market cap $73.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LNSR ranks #956 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LNSR compare to QTEX and MBOT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), LNSR carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 39.4%, and ROIC of -35.0%. By comparison, QTEX (QTREX Quantum Ltd.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $73.9M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, LNSR leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LNSR?

▼

Per LNSR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001320350), LENSAR Inc. generated $51.7M in revenue (+12.4% YoY), -$34.3M in net income, and -$14.9M in free cash flow against $71.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.81 (-0.58%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LNSR)Realized 20D OHLCV Swing Band: ±7%

Deterministic 5-Pillar Attribution (24/100 Composite)

🔍 WHY LNSR SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (33% of score)

20D Institutional Volume Accumulation (±7% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (25% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.37-8.9% Next Q

Q2 (-2Q)

Grade E$5.80+4.7% Next Q

Q3 (-1Q)

Grade E$6.07-3.8% Next Q

Current

Grade E$5.84-10.9% Hist 90D α

Trajectory: E (32) → E (24)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LNSR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LNSR currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.10) and Max Pain ($6.13) forces dealer call-delta covering toward $13.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LNSR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LNSR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 24%NO 76%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LNSR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $35.7M

FY24

Rev $46.0M

FY25

Rev $51.7M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$51.7M	39.4%	-47.6%	-$34.3M	-$14.9M	-45%
FY 2024	$46.0M	39.9%	-23.2%	-$31.4M	-$2.4M	-45%
FY 2023	$35.7M	39.4%	-34.2%	-$14.4M	-$9.7M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LNSR)

✓Walkthrough of LNSR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LNSR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.66%🛡️ HOLDING TREND SUPPORT

2026-10-30O $6.00H $6.03L $5.76C $5.84VOL 28.8K

RES: $7.20SUP: $5.77SMA50: $7.10SMA200: $7.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LNSR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LNSR Butterfly Map → + Track LNSR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +12.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LNSR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LNSR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LNSR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LNSR)

Health Care Rank #956 of 1016 ⚔️ QTEX vs LNSR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LNSR vs. QTEX, MBOT, DAVI, SKIN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LENSAR Inc. (LNSR) ranks #956 by composite RQD confidence (24/100, grade E) and #700 by equity capitalization ($73.3M). Within this direct 5-issuer industry benchmark cohort, LNSR leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DAVI currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with LNSR at 24/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LNSR ACTIVE LENSAR Inc.	E	24/100	—	39.4%	-35.0%	-2.18%	$73.3M	Benchmark Subject
QTEX QTREX Quantum Ltd.	E	31/100	—	0.7%	-35.0%	-7.58%	$73.9M	/qtex-vs-lnsr →
MBOT Microbot Medical Inc.	D-	41/100	—	—	-15.8%	-2.68%	$75.2M	/mbot-vs-lnsr →
DAVI Davion Healthcare Plc	D	47/100	—	—	—	-37.55%	$67.3M	/davi-vs-lnsr →
SKIN SkinHealth Systems Inc. (Class A)	D-	36/100	—	65.3%	-26.9%	-2.07%	$66.0M	/skin-vs-lnsr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001320350

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LENSAR Inc. (LNSR) reported GAAP revenue of $51.7M (+12.4% vs. FY2024 revenue of $46.0M , and +44.6% cumulative change since FY2023) , GAAP net income of -$34.3M, operating cash flow of -$14.8M, and free cash flow of -$14.9M (-513.5% YoY). On the balance sheet, LNSR closed FY2025 with $71.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$51.7M	-$34.3M	-$14.8M	-$14.9M	$71.4M	—
FY2024 (FY)	2024-12-31	$46.0M	-$31.4M	-$2.3M	-$2.4M	$66.3M	—
FY2023 (FY)	2023-12-31	$35.7M	-$14.4M	-$9.7M	-$9.7M	—	—

3. LNSR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LNSR compare to QTEX and MBOT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LNSR?

Where is LNSR trading relative to its 50-day, 200-day, and 52-week technical levels?

LNSR last traded at $5.84 (-2.18% on volume of 28,839 shares), positioning the stock -17.75% below its 50-day simple moving average ($7.10) and -21.61% below its 200-day simple moving average ($7.45). Across its 52-week range of $4.95 to $12.94, LNSR sits at the 11.1% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.0% ($5.43 to $6.25).

LNSR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is LENSAR Inc. (LNSR)?

In FY 2025 (10-K), LNSR converted $51.7M of revenue into a 39.4% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: LNSR RQD Cockpit LNSR 12M Forecast LNSR Earnings & Move LNSR Dividends & DRIP LNSR Insiders & 13F LNSR Whale Options LNSR Profit Sankey LNSR News & Why

Sector Peer Dials

Microbot Medical Inc.

41 /100

DAVI D

Davion Healthcare Plc

47 /100

SKIN D-

SkinHealth Systems Inc. (Class A)

36 /100

LUCD D

Lucid Diagnostics Inc.

LNSR Core Snapshot

Market Cap $73.3M

Trailing / Fwd P/E — / —

Gross Profit Margin 39.4%

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield -20.33%

12M Base Price Target $4.95

FREE TRADER TOOLS

Own LNSR Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With LNSR → 🏆 Trade LNSR in $100K Prop Arena →

LNSR Wire

Why It Moved →

Peer / Ecosystem Wire Stocktwits • 2h ago

Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback

Direct Company Event Yahoo Finance UK • 5h ago

LENSAR, Inc. (LNSR) Seasonal returns chart

Direct Company Event TradingView • 8h ago

LENSAR, Inc. Estimates – BOATS:LNSR

Direct Company Event Stock Traders Daily • 11h ago

(LNSR) Movement Within Algorithmic Entry Frameworks

Direct Company Event TradingView • 14h ago

LNSR Q3'26 Earnings: revenue estimate is 14.30M USD

ROARABLE RATING BRIEF • RQD 24/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LNSR — LENSAR Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:45:31Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LNSR scores 24 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 2/20 (ROIC -35%; FCF yield -20.33%), Whale 13F Flow at 8/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 5/20 (Altman Z 0.2; Piotroski F 4/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillar is the cash engine: negative ROIC and negative free cash flow yield indicate the business is not currently converting capital into owner returns. The forensic balance sheet pillar reinforces this concern, with an Altman Z-Score of 0.2 and a Piotroski F-Score of 4/9. The rating's upside case rests on the 8/20 institutional flow pillar and the 6/20 macro fit, which are the only pillars that score mid-range. Valuation tradeoffs are not resolvable from the source data because forward and trailing earnings multiples are not available. The rating characterizes the setup as forensic risk, and the scorecard does not identify a near-term fundamental catalyst that would offset the cash-flow and balance-sheet weakness.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$51.7M	$-24.6M	$-34.3M	N/A	$-14.9M	$13.0M	N/A
FY 2024	$46.0M	$-10.7M	$-31.4M	N/A	$-2.4M	$16.3M	N/A
FY 2023	$35.7M	$-12.2M	$-14.4M	N/A	$-9.7M	N/A	N/A

Per the SEC financials, revenue grew from $35.7M in FY 2023 to $51.7M in FY 2025, while operating losses widened to $-24.6M in FY 2025. Operating margin is -47.6% and net margin is -60% per the market data. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 0.2, and the Piotroski F-Score is 4/9. Debt/Equity is 0.5 per the rating. Cash fell from $16.3M in FY 2024 to $13.0M in FY 2025.

Recent Catalysts & News Wire Analysis

RISK WATCH (RED): A Stocktwits report headlined that LENSAR stock slumped after hours on ending a merger deal with Alcon over FTC pushback.
MARKET WIRE (YELLOW): Yahoo Finance UK seasonal returns chart; TradingView estimates listing; Stock Traders Daily algorithmic entry framework note; TradingView Q3'26 revenue estimate of 14.30M USD; a Stocktwits after-hours movement item referencing a different symbol (NUAI).
Butterfly Supply-Chain Graph: Supply chain status is NONE, with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies are mapped (supply_chain: NONE, butterfly_links: empty). Sector correlations and second-order bottlenecks are not available in source data. The most relevant second-order item from the news wire is the termination of the Alcon merger, which removes a potential strategic pathway; the implications for the company's operations are not available in source data.

Open Questions

What is the economic and regulatory impact of the terminated Alcon merger, and does it change the company's standalone funding path?
How will the company fund its operating losses given cash declined to $13.0M and FY 2025 free cash flow was $-14.9M?
What is the debt amount and structure, given debt is listed as N/A despite a Debt/Equity ratio of 0.5 in the rating?
What products and revenue streams drive the $51.7M in FY 2025 revenue, and which drove the widening operating loss?
What are the trailing and forward earnings figures, and how does the valuation compare to peers given the earnings multiples are not available?

LNSR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LENSAR Inc. (LNSR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LNSR Debate Forum (3) ↓

🔴 RISK WATCH Stocktwits • 2h ago

Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback

Stocktwits report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 5h ago

LENSAR, Inc. (LNSR) Seasonal returns chart

Yahoo Finance UK report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 8h ago

LENSAR, Inc. Estimates – BOATS:LNSR

TradingView report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 11h ago

(LNSR) Movement Within Algorithmic Entry Frameworks

Stock Traders Daily report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 14h ago

LNSR Q3'26 Earnings: revenue estimate is 14.30M USD

TradingView report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 17h ago

Why Did NUAI Stock Rise After Hours Today?

Stocktwits report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 20h ago

Price-Driven Insight from (LNSR) for Rule-Based Strategy

Stock Traders Daily report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 23h ago

LNSR Q2 2026 Earnings: EPS Swings to Profit, Beating Estimates by a Wide Margin - Earnings Surprise Stocks

https://www.dars.gov.et/ report covering LENSAR Inc. (LNSR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LNSR Bull vs. Bear Conversation Board — What's Your Call at $5.84?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LNSR 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $5.14 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LNSR (E • RQD 24/100) a Buy at $5.84?

Welcome to the LNSR (LENSAR Inc.) Roar Pit. Current RQD Composite is 24/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.67 (-20.0%)

Spot @ $5.84

Pump the brakes on LNSR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LNSR, but look at what you are paying: current EV/EBITDA multiples with 39.4% gross margins. Unless LENSAR Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.18 (+22.9%)

Spot @ $5.84

LNSR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LNSR, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $5.84 (52-wk range $4.95 - $12.94), any beat on forward guidance forces shorts and underweight funds to chase.